Literature DB >> 14558981

Do selective cyclo-oxygenase-2 nonsteroidal anti-inflammatory agents increase the risk for acute myocardial infarction?

Joseph S Alpert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14558981     DOI： 10.1007/s11886-003-0100-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


× No keyword cloud information.
  14 in total

Review 1.  Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.

Authors:  James E Dalen
Journal:  Arch Intern Med       Date:  2002-05-27

2.  Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Authors:  M A Konstam; M R Weir; A Reicin; D Shapiro; R S Sperling; E Barr; B J Gertz
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

Review 3.  Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors:  D Mukherjee; S E Nissen; E J Topol
Journal:  JAMA       Date:  2001 Aug 22-29       Impact factor: 56.272

4.  Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Authors:  J K Hennan; J Huang; T D Barrett; E M Driscoll; D E Willens; A M Park; L J Crofford; B R Lucchesi
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

5.  Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.

Authors:  Michael E Burleigh; Vladimir R Babaev; John A Oates; Raymond C Harris; Shiva Gautam; Denis Riendeau; Lawrence J Marnett; Jason D Morrow; Sergio Fazio; MacRae F Linton
Journal:  Circulation       Date:  2002-04-16       Impact factor: 29.690

6.  Association between naproxen use and protection against acute myocardial infarction.

Authors:  Elham Rahme; Louise Pilote; Jacques LeLorier
Journal:  Arch Intern Med       Date:  2002-05-27

7.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.

Authors:  Daniel H Solomon; Robert J Glynn; Raisa Levin; Jerry Avorn
Journal:  Arch Intern Med       Date:  2002-05-27

8.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

Authors:  William B White; Gerald Faich; Andrew Whelton; Clement Maurath; Nancy J Ridge; Kenneth M Verburg; G Steven Geis; James B Lefkowith
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

9.  Selective COX-2 inhibition improves endothelial function in coronary artery disease.

Authors:  Rémy Chenevard; David Hürlimann; Markus Béchir; Frank Enseleit; Lukas Spieker; Matthias Hermann; Walter Riesen; Steffen Gay; Renate E Gay; Michel Neidhart; Beat Michel; Thomas F Lüscher; Georg Noll; Frank Ruschitzka
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

10.  Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

Authors:  Andrew Whelton; William B White; Alfonso E Bello; Joseph A Puma; John G Fort
Journal:  Am J Cardiol       Date:  2002-11-01       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.